Implications of bedaquiline-resistant tuberculosis

Lancet Infect Dis. 2022 Feb;22(2):166-167. doi: 10.1016/S1473-3099(22)00008-1.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Diarylquinolines* / therapeutic use
  • Humans
  • Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

  • Diarylquinolines
  • bedaquiline